Sequence of <i>DpAP2</i> promoter. by Lingru Ruan (18995544)

Subjects:

Predicted <i>cis</i>-acting elements in <i>DpAP2</i> promoter. by Lingru Ruan (18995544)

Subjects:

Affinity analysis results (with a confidence level above 50%). by Marta R. Jabłońska (8491404)

rt-PA-induced lysis of different clot sizes. by Jan Víteček (11434774)

Subjects:

Complete data. by Jan Víteček (11434774)

Subjects:

Fig 4 - by Jan Víteček (11434774)

Subjects:

Degradation of clots of different ages. by Jan Víteček (11434774)

Subjects:

The dependency of thrombolysis on rt-PA concentration. by Jan Víteček (11434774)

Subjects:

Length of whole blood clots from different amounts of blood in the in vitro middle cerebral artery model (diameter 3.1 mm). by Jan Víteček (11434774)

Subjects:

The distributions of the end-simulation adolescence-limited proportion when (a) <i>k</i> is increased or decreased by 50%, (b) <i>c</i> is increased or decreased by 50%, (c) <i>γ</i> is increased or decreased by 50%, and (d) Δ<i>e</i> is increased or decreased by 50%, compared against the benchmark distribution <i>F</i>(<b>p</b>₀) for the parameters shown in Table 1. by Jia Ning Leaw (752775)

Expression of Egln3 decreases tumor aggression, increases survival and normalizes glioma vascular architecture. by Vicki A. Sciorra (312082)

Hydrogen peroxide-induced ROS formation is decreased in IRP1- cells. by Kurtis J. Haro (119844)

MEK5 expression decreases ER signaling and confers endocrine resistance. by James W. Antoon (444010)

Primary endpoint analysis, i.e., time to first occurrence of combined event of 50% decrease in eGFR or ESRD. by Rozita Mohd (7411322)

The number of cases of syphilis by classification in Japan showing as 100% stacked bar chart. by Akira Komori (8284599)

Detailed meta–analyses in untreated hypothyroid patients compared with controls for each HRV parameters: RR intervals, SDNN, RMSSD, pNN50, TP, LF, HF, LF/HF. by Valentin Brusseau (12769704)

Analysis of WST-1 assay. by Deepu Dowarha (5673440)

Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%. by Joseph Kamgno (81039)

“…<p>Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.…”

Decreased myofibroblasts in the peritumoral region and high expression of MMP-7 in Pan02 S.C. tumor of <i>S100a4-Cre; Ext1</i>^<i>f/f</i> mice. by Ayumi Niwa (6256790)

“…Data represent mean ± SEM (N = 6 for each cohort, Mann–Whitney test, unpaired t-test, respectively). Scale bar = 50 μm. (D) Microarray analysis of Pan02 S.C. tumor of <i>S100a4-Cre; Ext1</i>^<i>f/f</i> and control mice (N = 4 for each cohort). …”

In-phase (A) and opposed phase (B) chemical shift MR images of a 51-year-old male demonstrate hepatic steatosis, consistent with areas of decreased signal intensity on an opposed-p... by Andrzej Cieszanowski (635105)